Foto del docente

Elena Zamagni

Professoressa associata

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: MED/15 MALATTIE DEL SANGUE

Pubblicazioni

Jamet B.; Morvan L.; Nanni C.; Michaud A.-V.; Bailly C.; Chauvie S.; Moreau P.; Touzeau C.; Zamagni E.; Bodet-Milin C.; Kraeber-Bodere F.; Mateus D.; Carlier T., Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2021, 48, pp. 1005 - 1015 [articolo]

Zamagni E.; Dhanasiri S.; Ghale A.; Moore A.; Roussel M., Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens, «LEUKEMIA & LYMPHOMA», 2021, 62, pp. 2492 - 2501 [articolo]Open Access

Zamagni E.; Nanni C.; Dozza L.; Carlier T.; Bailly C.; Tacchetti P.; Versari A.; Chauvie S.; Gallamini A.; Gamberi B.; Caillot D.; Patriarca F.; Macro M.; Boccadoro M.; Garderet L.; Barbato S.; Fanti S.; Perrot A.; Gay F.; Sonneveld P.; Karlin L.; Cavo M.; Bodet-Milin C.; Moreau P.; Kraeber-Bodere F., Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 116 - 125 [articolo]

Rizzello I.; Cavo M.; Dozza L.; Rivolti E.; Petrucci M.T.; De Stefano V.; Antonioli E.; Tosi P.; D'Agostino M.; More S.; Gozzetti A.; Cea M.; Barbato S.; Tacchetti P.; Pantani L.; Mancuso K.; Rocchi S.; De Cicco G.; Fusco A.; Zamagni E., Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study, «LEUKEMIA & LYMPHOMA», 2021, 62, pp. 1897 - 1906 [articolo]

Terpos E.; Zamagni E.; Lentzsch S.; Drake M.T.; Garcia-Sanz R.; Abildgaard N.; Ntanasis-Stathopoulos I.; Schjesvold F.; de la Rubia J.; Kyriakou C.; Hillengass J.; Zweegman S.; Cavo M.; Moreau P.; San-Miguel J.; Dimopoulos M.A.; Munshi N.; Durie B.G.M.; Raje N., Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group, «THE LANCET ONCOLOGY», 2021, 22, pp. e119 - e130 [articolo]

Moreau P.; Kumar S.K.; San Miguel J.; Davies F.; Zamagni E.; Bahlis N.; Ludwig H.; Mikhael J.; Terpos E.; Schjesvold F.; Martin T.; Yong K.; Durie B.G.M.; Facon T.; Jurczyszyn A.; Sidana S.; Raje N.; van de Donk N.; Lonial S.; Cavo M.; Kristinsson S.Y.; Lentzsch S.; Hajek R.; Anderson K.C.; Joao C.; Einsele H.; Sonneveld P.; Engelhardt M.; Fonseca R.; Vangsted A.; Weisel K.; Baz R.; Hungria V.; Berdeja J.G.; Leal da Costa F.; Maiolino A.; Waage A.; Vesole D.H.; Ocio E.M.; Quach H.; Driessen C.; Blade J.; Leleu X.; Riva E.; Bergsagel P.L.; Hou J.; Chng W.J.; Mellqvist U.-H.; Dytfeld D.; Harousseau J.-L.; Goldschmidt H.; Laubach J.; Munshi N.C.; Gay F.; Beksac M.; Costa L.J.; Kaiser M.; Hari P.; Boccadoro M.; Usmani S.Z.; Zweegman S.; Holstein S.; Sezer O.; Harrison S.; Nahi H.; Cook G.; Mateos M.-V.; Rajkumar S.V.; Dimopoulos M.A.; Richardson P.G., Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, «THE LANCET ONCOLOGY», 2021, 22, pp. e105 - e118 [articolo]

Mattia D'agostino, Juan José Lahuerta, Anders Waage, Uta Bertsch, Elena Zamagni, Maria-Victoria Mateos, Alessandra Larocca, Daniele Dall'Olio, Niels WCJ van de Donk, Hans Salwender, Joan Bladé, Bronno van der Holt, Gastone Castellani, Giovannino Ciccone, Jan Dürig, Sara Bringhen, Sonja Zweegman, Michele Cavo, Hartmut Goldschmidt, Jesús María Hernandez Rivas, Jesus San Miguel, Mario Boccadoro, Pieter Sonneveld, A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM, in: Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020, «HEMASPHERE», 2020, 4, pp. 421 - 422 (atti di: 25th Congress of the European Hematology Association - 25th EHA Congress, Virtual edition, June 11-22, 2020) [atti di convegno-abstract]Open Access

Mattia D'Agostino, Juan-José Lahuerta, Ruth Wester, Anders Waage, Uta Bertsch, Elena Zamagni, Maria-Victoria Mateos, Alessandra Larocca, Daniele Dall'Olio, Niels W.C.J. Van De Donk, David Cairns, Serena Rocchi, Hans Salwender, Joan Blade Creixenti, Bronno van der Holt, Castellani Gastone, Giovannino Ciccone, Andrea Capra, Jan Dürig, Sara Bringhen, Sonja Zweegman, Michele Cavo, Hartmut Goldschmidt, Gordon Cook, Jesus Maria Hernández-Rivas, Jesus F. San-Miguel, Mario Boccadoro and Pieter Sonneveld, A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform, in: 62nd ASH Annual Meeting & Exposition, 2020(atti di: 62nd ASH Annual Meeting & Exposition, All-virtual event, December 5-8,2020) [atti di convegno-poster]

Facon T.; Dimopoulos M.A.; Meuleman N.; Belch A.; Mohty M.; Chen W.-M.; Kim K.; Zamagni E.; Rodriguez-Otero P.; Renwick W.; Rose C.; Tempescul A.; Boyle E.; Manier S.; Attal M.; Moreau P.; Macro M.; Leleu X.; Lorraine Chretien M.; Ludwig H.; Guo S.; Sturniolo M.; Tinel A.; Silvia Monzini M.; Costa B.; Houck V.; Hulin C.; Yves Mary J., A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial, «LEUKEMIA», 2020, 34, pp. 224 - 233 [articolo]

Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P., Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, «THE LANCET. HAEMATOLOGY», 2020, 7, pp. e456 - e468 [articolo]

Kastritis E.; Leleu X.; Arnulf B.; Zamagni E.; Cibeira M.T.; Kwok F.; Mollee P.; Hajek R.; Moreau P.; Jaccard A.; Schonland S.O.; Filshie R.; Nicolas-Virelizier E.; Augustson B.; Mateos M.-V.; Wechalekar A.; Hachulla E.; Milani P.; Dimopoulos M.A.; Fermand J.-P.; Foli A.; Gavriatopoulou M.; Klersy C.; Palumbo A.; Sonneveld P.; Erik Johnsen H.; Merlini G.; Palladini G., Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis, «JOURNAL OF CLINICAL ONCOLOGY», 2020, 38, pp. 3252 - 3260 [articolo]

Tacchetti P.; Pantani L.; Patriarca F.; Petrucci M.T.; Zamagni E.; Dozza L.; Galli M.; Di Raimondo F.; Crippa C.; Boccadoro M.; Barbato S.; Tosi P.; Narni F.; Montefusco V.; Testoni N.; Spadano A.; Terragna C.; Pescosta N.; Marzocchi G.; Cellini C.; Galieni P.; Ronconi S.; Gobbi M.; Catalano L.; Lazzaro A.; De Sabbata G.; Cangialosi C.; Ciambelli F.; Musto P.; Elice F.; Cavo M.; Fanin R.; Foa' R.; Rambaldi A.; Rossi G.; Leoni P.; Corradini P.; Torelli G.; Fioritoni G.; Cortelazzo S.; Lambertenghi Deliliers G.; La Nasa G.; Zaccaria A.; De Fabritiis P.; Cascavilla N.; Bosi A.; Semenzato G.; Gugliotta L.; Gherlinzoni F.; Angelucci E.; Martelli M.F.; Petti M.C.; Leone G.; Carella A.M.; Ciceri F.; Santoro A.; Ferrara F.; Nobile F.; D'Arco A.M.; Levis A.; Guardigni L.; Gallamini A.; Fattori P.P.; Morandi S.; Amadori D.; Rotoli B.; Mirto S.; Paladini G.; Mozzana R.; Pinotti G.; Rodeghiero F.; Cantore N.; Pavone V.; Pogliani E.M.; Liberati A.M.; Majolino I.; Amadori S.; Lauria F.; Aglietta M.; Quarta G.; Storti S.; Morabito F.; Capalbo S.F.; Gianni A.M.; Mettivier V.; Rizzoli V.; Bernasconi C.; Visani G.; Pizzuti M.; La Verde G.; Avvisati G.; Longinotti M.; Gallo E.; Dammacco F.; Russo D.; Bacigalupo A.; Musolino C., Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study, «THE LANCET. HAEMATOLOGY», 2020, 7, pp. 861 - 873 [articolo]

Jamet B.; Zamagni E.; Nanni C.; Bailly C.; Carlier T.; Touzeau C.; Michaud A.-V.; Moreau P.; Bodet-Milin C.; Kraeber-Bodere F., Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2020, 21, Article number: 5406, pp. 1 - 14 [articolo]Open Access

Michaud-Robert A.-V.; Zamagni E.; Carlier T.; Bailly C.; Jamet B.; Touzeau C.; Moreau P.; Kraeber-Bodere F.; Nanni C.; Bodet-Milin C., Glucose metabolism quantified by suvmax on baseline fdg-pet/ct predicts survival in newly diagnosed multiple myeloma patients: Combined harmonized analysis of two prospective phase iii trials, «CANCERS», 2020, 12, Article number: 2532, pp. 1 - 10 [articolo]Open Access

Mateos M.-V.; Kumar S.; Dimopoulos M.A.; Gonzalez-Calle V.; Kastritis E.; Hajek R.; De Larrea C.F.; Morgan G.J.; Merlini G.; Goldschmidt H.; Geraldes C.; Gozzetti A.; Kyriakou C.; Garderet L.; Hansson M.; Zamagni E.; Fantl D.; Leleu X.; Kim B.-S.; Esteves G.; Ludwig H.; Usmani S.; Min C.-K.; Qi M.; Ukropec J.; Weiss B.M.; Rajkumar S.V.; Durie B.G.M.; San-Miguel J., International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM), «BLOOD CANCER JOURNAL», 2020, 10, pp. 102 - 102 [articolo]Open Access